Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) Director Ken Takanashi purchased 22,053,581 shares of the business’s stock in a transaction that occurred on Tuesday, June 6th. The stock was bought at an average price of $0.91 per share, for a total transaction of $20,068,758.71. Following the purchase, the director now directly owns 24,847,694 shares in […]
Satsuma Pharmaceuticals (NASDAQ:STSA – Get Rating)‘s stock had its “neutral” rating reaffirmed by stock analysts at Mizuho in a research note issued on Thursday, Benzinga reports. They presently have a $2.00 price target on the financial services provider’s stock. Mizuho’s price target indicates a potential upside of 180.62% from the stock’s previous close. Satsuma Pharmaceuticals […]